Mezigdomide: New Drug Combination Trial Results for Multiple Myeloma Treatment

(10:24)

Mezigdomide in New Combos: Early Results for Relapsed/Refractory #Myeloma |Luciano Costa, MD| #ASH24

(4:15)

Preliminary Results of Mezigdomide Combinations in RRMM Patients | Luciano Costa, MD, PhD | IMS 2024

(3:29)

Mezigdomide For Myeloma | Therapies on the Horizon

(3:54)

Mezigdomide, dexamethasone and tazemetostat in patients with multiple myeloma in the CA057-003 trial

(2:7)

The impact of renal impairment on clinical outcomes with mezigdomide plus dex in R/R myeloma

(1:49)

Mezigdomide + dexamethasone in novel combinations for R/R myeloma: insights into the CA057-003 trial

(2:52)

Mezigdomide: a novel CELMoD showing promise in the treatment of R/R myeloma

(2:21)

Benefits of CELMoDs over IMiDs in multiple myeloma

(2:31)

Regional Myeloma Community Workshop

(2:59:18)

Symposium | Next wave of immune-based therapies: What you need to know, which focused on R/R MM

(19:41)

The Future of Myeloma Care | New York Roundtable October 19, 2024

(33:16)

Top Myeloma Research Presented at ASCO \u0026 EHA 2024

(1:2:1econd)

Cellular Therapy for the Treatment of Multiple Myeloma | Dr Michael Chu

(50:25)

Up and Coming Investigational Therapies in Myeloma | Detroit Roundtable October 12, 2024

(24:31)

IMWG Conference Series 2024: Making Sense of Treatment

(59:50)

The Latest Insights on Immune Therapies in Myeloma | 2023 IMF Patient and Family Seminar

(48:6)

IMF Patient \u0026 Family Webinar - Back to Basics: From Testing to Tailored Therapy

(2:50:58)

MPE webinar: ASH 2024 myeloma and AL amyloidosis highlights

(1:3:28)

Preliminary data on mezigdomide plus dexamethasone and bortezomib in R/R multiple myeloma

(2:41)

Mezigdomide, Tazemetostat, and Dex in RRMM: Results from CA057-003 | Luciano Costa, MD | EHA 2024

(3:42)

Iberdomide – efficacy and safety in RRMM

(4:16)

SUCCESSOR-2 rationale: mezigdomide in combination with carfilzomib \u0026 dexamethasone for R/R myeloma

(1:41)

Recent updates on CELMoDs in multiple myeloma

(1:55)

Treating and understanding the biology of extramedullary disease in myeloma

(1:41)

Mezigdomide Plus Dexamethasone in RRMM: CC-92480-MM-002 Trial Results| Paul Richardson, MD |ASH 2023

(2:47)

Mezigdomide Combined with Dex in Relapsed/Refractory MM Pts: CC-92480-MM-001 Trial

(10:45)

Insights into the CA057-003 trial: mezigdomide, tazemetostat \u0026 dexamethasone for R/R myeloma

(2:51)

ASH23: Mezigdomide (MEZI) Combo Therapy for Relapsed/Refractory Myeloma | Paul Richardson, MD

(11:42)